Are Charles River’s New Advanced Therapy Deals Quietly Rewriting Its Drug-Development Moat Story (CRL)?

• Earlier in March 2026, Locus Cell and Therna Biosciences each announced collaborations with Charles River Laboratories, pairing its global preclinical and analytical expertise with partners’ cell, gene, and RNA therapy platforms across Asia and ultra-rare disease settings.
• These agreements highlight how Charles River is embedding itself deeper into advanced therapies and personalized RNA medicine workflows, potentially reinforcing its role in high-complexity drug development services.
• We’ll now explore how these advanced therapy collaborations, alongside Charles River’s divestitures and cost actions, influence the company’s investment narrative.

Outshine the giants: these 19 early-stage AI stocks could fund your retirement.

Charles River Laboratories International Investment Narrative Recap

To own Charles River Laboratories, you need to believe that outsourced drug development, particularly in complex modalities, remains essential despite flat revenue guidance and recent losses. In the near term, the key catalyst is whether improving outsourcing demand can translate into a healthier book to bill, while the biggest risk is that lingering cancellations and funding constraints keep organic growth subdued. The new Locus Cell and Therna collaborations support the advanced therapies story but do not materially change those near term pressures yet.

The Therna Biosciences collaboration is especially relevant here, because it ties Charles River directly into individualized RNA programs for ultra rare diseases, an area where preclinical complexity is high and timelines are sensitive. If outsourcing trends and advanced therapy pipelines stabilize or improve, this type of work could support higher value testing flows, but it also heightens exposure to project specific delays and cancellations in a still fragile funding backdrop.

Yet behind these opportunities, investors should also be aware that rising non animal methods and shifting client preferences could eventually reshape Charles River’s core business...

Read the full narrative on Charles River Laboratories International (it's free!)

Charles River Laboratories International's narrative projects $4.4 billion revenue and $483.2 million earnings by 2028.

Uncover how Charles River Laboratories International's forecasts yield a $215.73 fair value, a 41% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were expecting revenue to reach about US$4.5 billion and earnings near US$665 million by 2028, but this bullish view on rapid adoption of new testing methods and margin expansion may need revisiting after partnerships like Therna and Locus Cell, which could either validate that thesis or highlight how uncertain these outcomes really are for you as an investor.

Explore 3 other fair value estimates on Charles River Laboratories International - why the stock might be worth over 2x more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Charles River Laboratories International research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Charles River Laboratories International research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Charles River Laboratories International's overall financial health at a glance.

Curious About Other Options?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Invest in the nuclear renaissance through our list of 87 elite nuclear energy infrastructure plays powering the global AI revolution.
• Find 47 companies with promising cash flow potential yet trading below their fair value.
• We've uncovered the 15 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com